3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
40
Lymphoid
33
Gastrointestinal
33
Genitourinary
29
Other hematologic neoplasm
28
Gynecologic
20
Thoracic
17
Plasma cell
17
Dermatologic
17
Head & Neck
16
Myeloid
13
CNS
11
Tumor-Agnostic
10
Sarcoma
7
Other
4
Classical hematology
4
Other solid neoplasm
1
Other neoplasm
1
Endocrine
1
Conditions
Multiple Endocrine Neoplasia Type 1
1
Depression
1
Alcoholism
1
Interventions
lutetium Lu 177 dotatate
36
Everolimus
32
pembrolizumab
24
Temozolomide
21
Magnetic Resonance Spectroscopy
21
Nivolumab
18
lenvatinib
17
gallium Ga 68 dotatate
16
cabozantinib
15
Cisplatin
15
lanreotide
14
3-Iodobenzylguanidine
14
Capecitabine
13
trametinib
12
dabrafenib
12
Bevacizumab
12
Octreotide
11
Surveys and Questionnaires
10
Surgical Procedures, Operative
10
Sunitinib
10
Radiosurgery
10
Positron Emission Tomography Computed Tomography
10
Blood Specimen Collection
10
Sorafenib
9
Paclitaxel
9
Ipilimumab
9
Carboplatin
9
surufatinib
8
Etoposide
8
Doxorubicin
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Therapeutics
×
Endocrine
×
Clear all
NCT00851669
2013-07-16
MEADOW/Bridge
University of Rochester
Phase 2
Completed
91 enrolled